| Technology Name | Briefcase | Lead Researcher |
|---|---|---|
At a Glance
Ayana Pharma is uniquely positioned to expand the uses and efficacy of the lipid-based cytotoxic drug’s well-established clinical profile. Invented by Prof. Yechezkel Barenholtz from the Hebrew University who is also the co-founder ... More | Barenholz Yechezkel | |
Category
LifeSciences and BioTechnology
Keywords
Therapeutic Agents, Liposomes, Biochemistry, Doxorubicin, Sulfate, Alkyl Sulfonate, DoxilTM
Application
Current preclinical and clinical data indicate that there is negligible release of ... More | Barenholz Yechezkel | |
Category
Life Sciences and Bio Technology
Keywords
Chemotherapy, Drug resistance * The project is conducted in collaboration with Memorial Sloan-Kettering Cancer Center.
Application
Cells with multidrug resistance (MDR) due to aberrant ... More | Barenholz Yechezkel | |
Company Name
LipoCure
Year Company was founded
2009
Company Founders
Prof. Yechezkel Barenholtz
Current CEO
Dr. Liana Patt, Ph. D., MBA
About the Company
LipoCure is developing a number of highly-potent therapeutics utilizing proprietary ... More | Barenholz Yechezkel | |
Categories
Drug Allergy, Drug Delivery, Nano-pharmaceuticals
Development Stage
TRL4, Successfully tested in large animals
Patent Status
US and Europe patent
Opportunity
Intravenous injection of some liposomal drugs, diagnostic agents, ... More | Barenholz Yechezkel | |
Keywords
Drug Delivery, Formulation
Current development stage
TRL7, Prototype and proprietary list of approved drugs that benefit from liposomal formulationsApplication
Most active pharmaceutical ingredients (APIs) are not suitable for ... More | Goldblum Amiram | |
The physical size of protein drugs and their susceptibility to degradation are key determinates that make them more dependent on drug delivery technologies. However formulating protein delivery systems so that they maintain their stability ... More | Barenholz Yechezkel |